Literature DB >> 8165708

Modulation of cytolytic T cell responses by heparan sulfate.

L E Wrenshall1, A Carlson, F B Cerra, J L Platt.   

Abstract

Accumulating evidence suggests that the functional properties of alloactivated T cells may depend upon the microenvironment in which the T cells reside. For instance, we showed previously that heparan sulfate, a biologically active polysaccharide present on cell surfaces and extracellular matrices, modulates the proliferative responses of splenocytes through enhancement of cytokine and prostaglandin production by macrophages. Here we report that under conditions of suboptimal stimulation, heparan sulfate causes discrete alterations in the functional responses of murine cytolytic T cells. When present in a 5-day mixed leukocyte culture (MLC), heparan sulfate mediates an increase, from 3- to 10-fold, in T cell-mediated cytotoxicity. This increase is dose dependent and most pronounced when heparan sulfate is present in the highest concentration during the first 24 hr of the culture period. On the other hand, when added during the last 48-72 hr of an MLC, heparan sulfate decreases cytotoxicity by 3- to 30-fold. Neutralizing antibodies against IL-1 alpha, but not antibodies against IL1 beta, IL-6, or TNF alpha/beta, abrogate the heparan sulfate-mediated increase in cytotoxicity, suggesting that the increase depended in part upon the production of IL-1 alpha. However, studies in which exogenous IL-1 was added to MLC showed that increased cytotoxicity was not due only to increased cytokine production. Augmentation of cytotoxicity was in part independent of T cell help, as depletion of CD4+ cells from the responder population before MLC, or addition of neutralizing anti-murine IL-2 antibodies plus human IL-2 to the MLC, did not abrogate the stimulatory effect of heparan sulfate. Heparan sulfate-treated CD8+ lymphoblasts isolated after 7 days in MLC demonstrated an increased cytotoxicity, elevated intracellular serine esterase, and perforin levels compared with lymphoblasts from control MLC. The decrease in cytotoxicity observed when heparan sulfate was present during the last several days of an MLC was likely mediated by PGE2, as elevated levels of PGE2 were detected in MLC supernatants of heparan sulfate-treated cultures, and because the decrease was not observed in the presence of indomethacin. Our results are consistent with the idea that the metabolism of heparan sulfate, an endogenous component of parenchymal tissues, may regulate the tempo and magnitude of alloreactive cytotoxic T cell responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165708

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

Review 2.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

3.  Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44.

Authors:  C M McKee; M B Penno; M Cowman; M D Burdick; R M Strieter; C Bao; P W Noble
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

Review 4.  Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues.

Authors:  Jeffrey L Platt; Lucile E Wrenshall; Geoffrey B Johnson; Marilia Cascalho
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

5.  Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice.

Authors:  Nadine Nagy; Gernot Kaber; Michael J Kratochvil; Hedwich F Kuipers; Shannon M Ruppert; Koshika Yadava; Jason Yang; Sarah C Heilshorn; S Alice Long; Alberto Pugliese; Paul L Bollyky
Journal:  Diabetologia       Date:  2020-10-30       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.